# A Study in Subjects With Human Papillomavirus 16 or 18 Associated Cervical Intraepithelial Neoplasia Grade 2 or 3

Clinical trial · RinuaGene Biotechnology Co., Ltd.

- Archive id: nct:NCT06273553
- Published: 2024-02-22
- Venue: ClinicalTrials.gov
- ClinicalTrials.gov: https://clinicaltrials.gov/study/NCT06273553
- Source URL: https://clinicaltrials.gov/study/NCT06273553
- Provenance: clinicaltrials

## Abstract

The purpose of this study is to to evaluate the safety, tolerability, immunogenicity, and efficacy of RG002 Injection in subjects with HPV16/18 associated Cervical Intraepithelial Neoplasia Grade 2 or 3(CIN2/3).

_Abstract reproduced under ClinicalTrials.gov (U.S. National Library of Medicine), data processed 2026-10-29T09:00:05; modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters._

## Trial details

- status: NOT_YET_RECRUITING
- phase: PHASE1, PHASE2
- study type: INTERVENTIONAL
- enrollment: 39
- sponsor: RinuaGene Biotechnology Co., Ltd.
- conditions: Human Papillomavirus Associated Intraepithelial Neoplasia; Cervical Intraepithelial Neoplasia Grade 2/3; Human Papillomavirus Type 16 Infection; Human Papillomavirus Type 18 Infection
- interventions: BIOLOGICAL: RG002 injection
- start date: 2024-03-01
- start date type: ESTIMATED
- primary completion date: 2026-10-01
- has results: false
- data source: ClinicalTrials.gov
- data processed: 2026-10-29T09:00:05
- modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters

Topics: [mRNA Therapeutics & Cancer Vaccines](https://space-kitty.com/topics/mrna-cancer-vaccines)

---
Space Kitty Archive · https://space-kitty.com · API: https://space-kitty.com/api/v1 · MCP: https://space-kitty.com/mcp · Premium: $0.20/request via x402 (Base Sepolia (testnet)). Metadata: arXiv (CC0), OpenAlex (CC0), Europe PMC (CC BY/CC0 works), ClinicalTrials.gov.